Datopotamab Deruxtecan, often abbreviated as DATO, represents a notable advancement within targeted cancer care. This new antibody-drug conjugate pairs the monoclonal antibody specifically directed at HER2 expressing https://xanderxmtq666048.activoblog.com/51385217/data-deruxtecan-an-encouraging-antibody-drug-conjugate